164P Roginolisib (IOA-244), the first highly selective oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ), has immuno-modulatory effects associated with clinical benefits in patients with metastatic uveal melanoma
Roginolisib continuously administered inhibits its target at IC90 in patients (pts). In pts with pretreated uveal melanoma (UM), a median overall survival (OS) of 15.9 months (m) (CI95%:10.7-26.4 m) and median PFS of 5.3 m (CI95% 3.7-5.9) was observed. Biomarker data from the completed Phase I DIONE-01 study may explain the mechanism of action of roginolisib.
Authors
- P. Brodin
- J. Graham
- T. Lakshmikanth
- M. Simonelli
- C. Carlo-Stella
- T. Hammett
- G. Amato
- Michael Lahn (ORCID: https://orcid.org/0000-0002-1377-7308)
- Paramjit Kaur (ORCID: https://orcid.org/0000-0003-4014-9064)
- M. Maio
- Giusy Di Conza (ORCID: https://orcid.org/0000-0003-1353-5867)
- T. Ziyang
- A. Santoro
- P. Spiliopoulou
- E. Simonetti
- F. Santangelo
- M. Occhipinti
- T.R.J. Evans
- Anna Maria Di Giacomo
Institutions
- University of Siena (IT)
- Humanitas University (IT)
- University of Liège (BE)
- Beatson West of Scotland Cancer Centre (GB)
- Karolinska Institutet (SE)
- Ospedale Santa Maria alle Scotte (IT)
- University Hospital of Geneva (CH)
- Azienda Ospedaliera Universitaria Senese (IT)
- Fondazione Humanitas per la Ricerca (IT)
- University of Glasgow (GB)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2024.100793
- Citations
- 1
- Primary Topic
- Ocular Oncology and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.54